Literature DB >> 1358115

Benzodiazepine antagonists. An update of their role in the emergency care of overdose patients.

P J Kulka1, P M Lauven.   

Abstract

The benzodiazepine antagonist flumazenil is a very valuable tool in the diagnosis and treatment of intoxications in which benzodiazepines are involved. In case of a positive response, patients will regain consciousness immediately, thus verifying the diagnosis and making a brief history possible to identify other drugs that might be involved. Moreover, invasive diagnostic and therapeutic procedures like gastric lavage, lumbar puncture, mechanical ventilation, etc., may then be unnecessary. In cases of pure benzodiazepine overdose a single injection of flumazenil 0.2mg should be given, followed by individually titrated increments of 0.1 mg/min until the patient is awake and responsive. In these cases a total dose of 2mg is usually sufficient. Higher doses of flumazenil may be necessary in cases of combined drug overdose. Because of its high therapeutic index, the administration of flumazenil is usually not accompanied by serious adverse effects. Benzodiazepine withdrawal syndromes characterised by transient anxiety and depression can occur, but the incidence is low. Increases of blood pressure and heart rate due to a release of catecholamines are possible, which might endanger patients with cardiovascular diseases. In severe cases, seizures have been observed which usually respond well to small doses of benzodiazepine agonists. In all cases of successful treatment it should be remembered that the effect of flumazenil deteriorates after 1 to 2h, which usually leads at first to resedation. In these patients additional bolus injections or a continuous infusion (0.1 to 0.5 mg/h) may be necessary. The effectiveness of flumazenil in cases of alcohol (ethanol) poisoning is questionable and should be further investigated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358115     DOI: 10.2165/00002018-199207050-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  39 in total

1.  Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol?

Authors:  U Klotz; G Ziegler; B Rosenkranz; G Mikus
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

2.  The diagnostic utility of flumazenil (a benzodiazepine antagonist) in coma of unknown etiology.

Authors:  K K Burkhart; K W Kulig
Journal:  Ann Emerg Med       Date:  1990-03       Impact factor: 5.721

Review 3.  Anaesthesia techniques for midazolam and flumazenil--an overview.

Authors:  P M Lauven; P J Kulka
Journal:  Acta Anaesthesiol Scand Suppl       Date:  1990

4.  Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.

Authors:  G Roncari; W H Ziegler; T W Guentert
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

5.  Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients.

Authors:  P Hartvig; L Wiklund; B Lindström
Journal:  Acta Anaesthesiol Scand       Date:  1986-02       Impact factor: 2.105

6.  Physostigmine reversal of midazolam-induced sedation.

Authors:  C B Caldwell; J B Gross
Journal:  Anesthesiology       Date:  1982-08       Impact factor: 7.892

7.  Specific treatment of benzodiazepine overdose.

Authors:  P Lheureux; R Askenasi
Journal:  Hum Toxicol       Date:  1988-03

8.  Flumazenil in the management of acute drug overdosage with benzodiazepines and other agents.

Authors:  G F O'Sullivan; D N Wade
Journal:  Clin Pharmacol Ther       Date:  1987-09       Impact factor: 6.875

Review 9.  Pharmacokinetics and clinical use of flumazenil (Ro 15-1788).

Authors:  U Klotz; J Kanto
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

10.  Admission to a pediatric intensive care unit for poisoning: a review of 105 cases.

Authors:  J Lacroix; P Gaudreault; M Gauthier
Journal:  Crit Care Med       Date:  1989-08       Impact factor: 7.598

View more
  2 in total

Review 1.  A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose.

Authors:  A A Weinbroum; R Flaishon; P Sorkine; O Szold; V Rudick
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

2.  Comparative study of hemodynamic changes caused by diazepam and midazolam during third molar surgery: a randomized controlled trial.

Authors:  Hécio Henrique Araújo de Morais; Jimmy Charles Melo Barbalho; Ricardo José de Holanda Vasconcellos; Fabricio Souza Landim; Fábio Andrey da Costa Araújo; Tasiana Guedes de Souza Dias
Journal:  Oral Maxillofac Surg       Date:  2015-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.